

Global Alpha-emitting Radiopharmaceutical Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G66C959EDF74EN.html>

Date: July 2026

Pages: 117

Price: US\$ 3,660.00 (Single User License)

ID: G66C959EDF74EN

Abstracts

The global Alpha-emitting Radiopharmaceutical market size is predicted to grow from US\$ 216 million in 2025 to US\$ 324 million in 2032; it is expected to grow at a CAGR of 6.6% from 2026 to 2032.

Alpha-emitting Radiopharmaceuticals are innovative therapeutic radiopharmaceuticals that use alpha-particle-emitting radionuclides as the core cytotoxic payload and deliver them precisely to tumor cells or disease microenvironments through small molecules, antibodies, peptides, ligands, or other targeting vectors. By releasing high-linear-energy-transfer radiation, they can induce double-strand DNA breaks and potent tumor cell killing. Compared with conventional external beam radiotherapy or certain beta-emitting radiopharmaceuticals, alpha particles have a shorter tissue range and higher energy density, enabling strong localized tumor destruction while potentially reducing unnecessary exposure to surrounding healthy tissues. This product category integrates nuclear medicine, targeted oncology, radiochemistry, isotope supply, companion diagnostics, and precision medicine, making it a frontier field in the evolution of radiopharmaceuticals from diagnosis to therapy and from single indications to broader oncology applications. The average gross profit margin of this product is 93%.

Alpha-emitting radiopharmaceuticals are entering a strategic window where nuclear medicine therapy and precision oncology are converging. As the clinical value of radioligand therapy continues to gain recognition globally, pharmaceutical companies, investors, and clinical institutions are showing growing interest in the model of ?diagnosis-guided precision killing.? The core appeal of alpha-emitting radiopharmaceuticals lies in their high energy, short tissue range, and strong ability to induce DNA damage, making them particularly attractive for minimal residual disease, heterogeneous solid tumors, bone metastases, and patient populations resistant to

conventional therapies. The active investment of major pharmaceutical companies in radioconjugates, actinium-based platforms, and isotope supply chains is accelerating the field from early-stage research toward industrial competition. For CEOs, marketing leaders, and investors, alpha-emitting radiopharmaceuticals represent not only a new drug category but also a strategic entry point into targeted oncology, nuclear medicine infrastructure, and next-generation precision therapy platforms.

The challenges of alpha-emitting radiopharmaceuticals arise from the combined complexity of technology, regulation, manufacturing, and clinical translation. First, alpha-emitting radionuclides involve demanding requirements related to half-life, decay chains, daughter isotope migration, and radiochemical stability, meaning drug design must simultaneously achieve targeting efficiency, in vivo stability, and a safe therapeutic window. Second, radiopharmaceutical manufacturing requires specialized licenses, shielding facilities, hot cells, automated synthesis modules, radioactive waste management, and stringent GMP systems, creating significantly higher barriers than conventional innovative drugs. Third, clinical implementation depends on close collaboration among nuclear medicine, oncology, imaging, pharmacy, and radiation safety teams, while treatment-center readiness and patient workflow directly shape commercialization speed. At the same time, bone marrow suppression, renal toxicity, salivary gland injury, dosimetry assessment, and long-term safety remain core risks that companies must address seriously during clinical development and market access.

Downstream demand for alpha-emitting radiopharmaceuticals will evolve rapidly around difficult-to-treat cancers, precision patient stratification, and integrated diagnosis-treatment pathways. Oncology hospitals, nuclear medicine departments in general hospitals, prostate cancer centers, neuroendocrine tumor centers, bone metastasis treatment centers, and innovative drug clinical research institutions will become key early-use and market education settings. As PET/SPECT imaging, target testing, molecular profiling, and dosimetry management mature, downstream customers will evaluate these products not only by therapeutic efficacy but also by target selection, imaging confirmation, treatment accessibility, toxicity management, and multidisciplinary workflow efficiency. Future demand will no longer focus simply on whether a new radiopharmaceutical is available, but on whether a complete solution can be built from diagnosis, patient screening, dosing, monitoring, and retreatment. This will give stronger competitive advantages to companies with integrated pipelines, nuclear medicine channels, and treatment-center collaboration capabilities.

LPI (LP Information)' newest research report, the "Alpha-emitting Radiopharmaceutical Industry Forecast" looks at past sales and reviews total world Alpha-emitting

Radiopharmaceutical sales in 2025, providing a comprehensive analysis by region and market sector of projected Alpha-emitting Radiopharmaceutical sales for 2026 through 2032. With Alpha-emitting Radiopharmaceutical sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Alpha-emitting Radiopharmaceutical industry.

This Insight Report provides a comprehensive analysis of the global Alpha-emitting Radiopharmaceutical landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Alpha-emitting Radiopharmaceutical portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Alpha-emitting Radiopharmaceutical market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Alpha-emitting Radiopharmaceutical and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Alpha-emitting Radiopharmaceutical.

This report presents a comprehensive overview, market shares, and growth opportunities of Alpha-emitting Radiopharmaceutical market by product type, application, key players and key regions and countries.

Segmentation by Type:

Actinium-225 Radiopharmaceuticals

Radium-223 Radiopharmaceuticals

Lead-212 Radiopharmaceuticals

Astatine-211 Radiopharmaceuticals

Bismuth-213 Radiopharmaceuticals

Other

Segmentation by Indication:

Prostate Cancer Targeted Agents

Neuroendocrine Tumor Agents

Hematologic Malignancy Agents

Solid Tumor Agents

Companion Diagnostic Enabled

Other

Segmentation by Supply Form:

Ready-To-Use Injection

Radiolabeling Kit

Isotope Precursor

Other

Segmentation by Application:

Prostate Cancer

Bone Metastases

Neuroendocrine Tumors

Hematologic Malignancies

Other Solid Tumors

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Bayer

Novartis

Eli Lilly

AstraZeneca

Fusion Pharmaceuticals

Telix Pharmaceuticals

RayzeBio

Orano Med

Actinium Pharmaceuticals

Alpha-9 Theranostics

AdvanCell

ITM Isotope Technologies Munich

Curium

China Isotope & Radiation

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Alpha-emitting Radiopharmaceutical Market Size (2021-2032)
 - 2.1.2 Alpha-emitting Radiopharmaceutical Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for Alpha-emitting Radiopharmaceutical by Country/Region (2021, 2025 & 2032)
- 2.2 Alpha-emitting Radiopharmaceutical Segment by Type
 - 2.2.1 Actinium-225 Radiopharmaceuticals
 - 2.2.2 Radium-223 Radiopharmaceuticals
 - 2.2.3 Lead-212 Radiopharmaceuticals
 - 2.2.4 Astatine-211 Radiopharmaceuticals
 - 2.2.5 Bismuth-213 Radiopharmaceuticals
 - 2.2.6 Other
 - 2.2.7 Alpha-emitting Radiopharmaceutical Market Size by Type
 - 2.2.7.1 Alpha-emitting Radiopharmaceutical Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.7.2 Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2021-2026)
- 2.3 Alpha-emitting Radiopharmaceutical Segment by Indication
 - 2.3.1 Prostate Cancer Targeted Agents
 - 2.3.2 Neuroendocrine Tumor Agents
 - 2.3.3 Hematologic Malignancy Agents
 - 2.3.4 Solid Tumor Agents
 - 2.3.5 Companion Diagnostic Enabled

2.3.6 Other

2.3.7 Alpha-emitting Radiopharmaceutical Market Size by Indication

2.3.7.1 Alpha-emitting Radiopharmaceutical Market Size CAGR by Indication (2021 VS 2025 VS 2032)

2.3.7.2 Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication (2021-2026)

2.4 Alpha-emitting Radiopharmaceutical Segment by Supply Form

2.4.1 Ready-To-Use Injection

2.4.2 Radiolabeling Kit

2.4.3 Isotope Precursor

2.4.4 Other

2.4.5 Alpha-emitting Radiopharmaceutical Market Size by Supply Form

2.4.5.1 Alpha-emitting Radiopharmaceutical Market Size CAGR by Supply Form (2021 VS 2025 VS 2032)

2.4.5.2 Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form (2021-2026)

2.5 Alpha-emitting Radiopharmaceutical Segment by Application

2.5.1 Prostate Cancer

2.5.2 Bone Metastases

2.5.3 Neuroendocrine Tumors

2.5.4 Hematologic Malignancies

2.5.5 Other Solid Tumors

2.5.6 Other

2.5.7 Alpha-emitting Radiopharmaceutical Market Size by Application

2.5.7.1 Alpha-emitting Radiopharmaceutical Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.5.7.2 Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2026)

3 ALPHA-EMITTING RADIOPHARMACEUTICAL MARKET SIZE BY PLAYER

3.1 Alpha-emitting Radiopharmaceutical Market Size Market Share by Player

3.1.1 Global Alpha-emitting Radiopharmaceutical Revenue by Player (2021-2026)

3.1.2 Global Alpha-emitting Radiopharmaceutical Revenue Market Share by Player (2021-2026)

3.2 Global Alpha-emitting Radiopharmaceutical Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 ALPHA-EMITTING RADIOPHARMACEUTICAL BY REGION

- 4.1 Alpha-emitting Radiopharmaceutical Market Size by Region (2021-2026)
- 4.2 Global Alpha-emitting Radiopharmaceutical Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Alpha-emitting Radiopharmaceutical Market Size Growth (2021-2026)
- 4.4 APAC Alpha-emitting Radiopharmaceutical Market Size Growth (2021-2026)
- 4.5 Europe Alpha-emitting Radiopharmaceutical Market Size Growth (2021-2026)
- 4.6 Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size Growth (2021-2026)

5 AMERICAS

- 5.1 Americas Alpha-emitting Radiopharmaceutical Market Size by Country (2021-2026)
- 5.2 Americas Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026)
- 5.3 Americas Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Alpha-emitting Radiopharmaceutical Market Size by Region (2021-2026)
- 6.2 APAC Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026)
- 6.3 APAC Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Alpha-emitting Radiopharmaceutical Market Size by Country (2021-2026)
- 7.2 Europe Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026)
- 7.3 Europe Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Alpha-emitting Radiopharmaceutical by Region (2021-2026)
- 8.2 Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026)
- 8.3 Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL ALPHA-EMITTING RADIOPHARMACEUTICAL MARKET FORECAST

- 10.1 Global Alpha-emitting Radiopharmaceutical Forecast by Region (2027-2032)
 - 10.1.1 Global Alpha-emitting Radiopharmaceutical Forecast by Region (2027-2032)
 - 10.1.2 Americas Alpha-emitting Radiopharmaceutical Forecast
 - 10.1.3 APAC Alpha-emitting Radiopharmaceutical Forecast
 - 10.1.4 Europe Alpha-emitting Radiopharmaceutical Forecast
 - 10.1.5 Middle East & Africa Alpha-emitting Radiopharmaceutical Forecast
- 10.2 Americas Alpha-emitting Radiopharmaceutical Forecast by Country (2027-2032)

- 10.2.1 United States Market Alpha-emitting Radiopharmaceutical Forecast
- 10.2.2 Canada Market Alpha-emitting Radiopharmaceutical Forecast
- 10.2.3 Mexico Market Alpha-emitting Radiopharmaceutical Forecast
- 10.2.4 Brazil Market Alpha-emitting Radiopharmaceutical Forecast
- 10.3 APAC Alpha-emitting Radiopharmaceutical Forecast by Region (2027-2032)
 - 10.3.1 China Alpha-emitting Radiopharmaceutical Market Forecast
 - 10.3.2 Japan Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.3.3 Korea Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.3.4 Southeast Asia Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.3.5 India Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.3.6 Australia Market Alpha-emitting Radiopharmaceutical Forecast
- 10.4 Europe Alpha-emitting Radiopharmaceutical Forecast by Country (2027-2032)
 - 10.4.1 Germany Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.4.2 France Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.4.3 UK Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.4.4 Italy Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.4.5 Russia Market Alpha-emitting Radiopharmaceutical Forecast
- 10.5 Middle East & Africa Alpha-emitting Radiopharmaceutical Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.5.2 South Africa Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.5.3 Israel Market Alpha-emitting Radiopharmaceutical Forecast
 - 10.5.4 Turkey Market Alpha-emitting Radiopharmaceutical Forecast
- 10.6 Global Alpha-emitting Radiopharmaceutical Forecast by Type (2027-2032)
- 10.7 Global Alpha-emitting Radiopharmaceutical Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Alpha-emitting Radiopharmaceutical Forecast

11 KEY PLAYERS ANALYSIS

11.1 Bayer

- 11.1.1 Bayer Company Information
- 11.1.2 Bayer Alpha-emitting Radiopharmaceutical Product Offered
- 11.1.3 Bayer Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)
- 11.1.4 Bayer Main Business Overview
- 11.1.5 Bayer Latest Developments

11.2 Novartis

- 11.2.1 Novartis Company Information
- 11.2.2 Novartis Alpha-emitting Radiopharmaceutical Product Offered

11.2.3 Novartis Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.2.4 Novartis Main Business Overview

11.2.5 Novartis Latest Developments

11.3 Eli Lilly

11.3.1 Eli Lilly Company Information

11.3.2 Eli Lilly Alpha-emitting Radiopharmaceutical Product Offered

11.3.3 Eli Lilly Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.3.4 Eli Lilly Main Business Overview

11.3.5 Eli Lilly Latest Developments

11.4 AstraZeneca

11.4.1 AstraZeneca Company Information

11.4.2 AstraZeneca Alpha-emitting Radiopharmaceutical Product Offered

11.4.3 AstraZeneca Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.4.4 AstraZeneca Main Business Overview

11.4.5 AstraZeneca Latest Developments

11.5 Fusion Pharmaceuticals

11.5.1 Fusion Pharmaceuticals Company Information

11.5.2 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product Offered

11.5.3 Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 Fusion Pharmaceuticals Main Business Overview

11.5.5 Fusion Pharmaceuticals Latest Developments

11.6 Telix Pharmaceuticals

11.6.1 Telix Pharmaceuticals Company Information

11.6.2 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product Offered

11.6.3 Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.6.4 Telix Pharmaceuticals Main Business Overview

11.6.5 Telix Pharmaceuticals Latest Developments

11.7 RayzeBio

11.7.1 RayzeBio Company Information

11.7.2 RayzeBio Alpha-emitting Radiopharmaceutical Product Offered

11.7.3 RayzeBio Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.7.4 RayzeBio Main Business Overview

11.7.5 RayzeBio Latest Developments

11.8 Orano Med

11.8.1 Orano Med Company Information

11.8.2 Orano Med Alpha-emitting Radiopharmaceutical Product Offered

11.8.3 Orano Med Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.8.4 Orano Med Main Business Overview

11.8.5 Orano Med Latest Developments

11.9 Actinium Pharmaceuticals

11.9.1 Actinium Pharmaceuticals Company Information

11.9.2 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product Offered

11.9.3 Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.9.4 Actinium Pharmaceuticals Main Business Overview

11.9.5 Actinium Pharmaceuticals Latest Developments

11.10 Alpha-9 Theranostics

11.10.1 Alpha-9 Theranostics Company Information

11.10.2 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product Offered

11.10.3 Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.10.4 Alpha-9 Theranostics Main Business Overview

11.10.5 Alpha-9 Theranostics Latest Developments

11.11 AdvanCell

11.11.1 AdvanCell Company Information

11.11.2 AdvanCell Alpha-emitting Radiopharmaceutical Product Offered

11.11.3 AdvanCell Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.11.4 AdvanCell Main Business Overview

11.11.5 AdvanCell Latest Developments

11.12 ITM Isotope Technologies Munich

11.12.1 ITM Isotope Technologies Munich Company Information

11.12.2 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product Offered

11.12.3 ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.12.4 ITM Isotope Technologies Munich Main Business Overview

11.12.5 ITM Isotope Technologies Munich Latest Developments

11.13 Curium

11.13.1 Curium Company Information

11.13.2 Curium Alpha-emitting Radiopharmaceutical Product Offered

11.13.3 Curium Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.13.4 Curium Main Business Overview

11.13.5 Curium Latest Developments

11.14 China Isotope & Radiation

11.14.1 China Isotope & Radiation Company Information

11.14.2 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product Offered

11.14.3 China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue, Gross Margin and Market Share (2021-2026)

11.14.4 China Isotope & Radiation Main Business Overview

11.14.5 China Isotope & Radiation Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Alpha-emitting Radiopharmaceutical Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Alpha-emitting Radiopharmaceutical Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Actinium-225 Radiopharmaceuticals

Table 4. Major Players of Radium-223 Radiopharmaceuticals

Table 5. Major Players of Lead-212 Radiopharmaceuticals

Table 6. Major Players of Astatine-211 Radiopharmaceuticals

Table 7. Major Players of Bismuth-213 Radiopharmaceuticals

Table 8. Major Players of Other

Table 9. Alpha-emitting Radiopharmaceutical Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 10. Global Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026) & (\$ millions)

Table 11. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2021-2026)

Table 12. Major Players of Prostate Cancer Targeted Agents

Table 13. Major Players of Neuroendocrine Tumor Agents

Table 14. Major Players of Hematologic Malignancy Agents

Table 15. Major Players of Solid Tumor Agents

Table 16. Major Players of Companion Diagnostic Enabled

Table 17. Major Players of Other

Table 18. Alpha-emitting Radiopharmaceutical Market Size CAGR by Indication (2021 VS 2025 VS 2032) & (\$ millions)

Table 19. Global Alpha-emitting Radiopharmaceutical Market Size by Indication (2021-2026) & (\$ millions)

Table 20. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication (2021-2026)

Table 21. Major Players of Ready-To-Use Injection

Table 22. Major Players of Radiolabeling Kit

Table 23. Major Players of Isotope Precursor

Table 24. Major Players of Other

Table 25. Alpha-emitting Radiopharmaceutical Market Size CAGR by Supply Form (2021 VS 2025 VS 2032) & (\$ millions)

Table 26. Global Alpha-emitting Radiopharmaceutical Market Size by Supply Form

(2021-2026) & (\$ millions)

Table 27. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form (2021-2026)

Table 28. Alpha-emitting Radiopharmaceutical Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 29. Global Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026) & (\$ millions)

Table 30. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2026)

Table 31. Global Alpha-emitting Radiopharmaceutical Revenue by Player (2021-2026) & (\$ millions)

Table 32. Global Alpha-emitting Radiopharmaceutical Revenue Market Share by Player (2021-2026)

Table 33. Alpha-emitting Radiopharmaceutical Key Players Head office and Products Offered

Table 34. Alpha-emitting Radiopharmaceutical Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 35. New Products and Potential Entrants

Table 36. Mergers & Acquisitions, Expansion

Table 37. Global Alpha-emitting Radiopharmaceutical Market Size by Region (2021-2026) & (\$ millions)

Table 38. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Region (2021-2026)

Table 39. Global Alpha-emitting Radiopharmaceutical Revenue by Country/Region (2021-2026) & (\$ millions)

Table 40. Global Alpha-emitting Radiopharmaceutical Revenue Market Share by Country/Region (2021-2026)

Table 41. Americas Alpha-emitting Radiopharmaceutical Market Size by Country (2021-2026) & (\$ millions)

Table 42. Americas Alpha-emitting Radiopharmaceutical Market Size Market Share by Country (2021-2026)

Table 43. Americas Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026) & (\$ millions)

Table 44. Americas Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2021-2026)

Table 45. Americas Alpha-emitting Radiopharmaceutical Market Size by Application (2021-2026) & (\$ millions)

Table 46. Americas Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2026)

Table 47. APAC Alpha-emitting Radiopharmaceutical Market Size by Region
(2021-2026) & (\$ millions)

Table 48. APAC Alpha-emitting Radiopharmaceutical Market Size Market Share by
Region (2021-2026)

Table 49. APAC Alpha-emitting Radiopharmaceutical Market Size by Type (2021-2026)
& (\$ millions)

Table 50. APAC Alpha-emitting Radiopharmaceutical Market Size by Application
(2021-2026) & (\$ millions)

Table 51. Europe Alpha-emitting Radiopharmaceutical Market Size by Country
(2021-2026) & (\$ millions)

Table 52. Europe Alpha-emitting Radiopharmaceutical Market Size Market Share by
Country (2021-2026)

Table 53. Europe Alpha-emitting Radiopharmaceutical Market Size by Type
(2021-2026) & (\$ millions)

Table 54. Europe Alpha-emitting Radiopharmaceutical Market Size by Application
(2021-2026) & (\$ millions)

Table 55. Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size by
Region (2021-2026) & (\$ millions)

Table 56. Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size by
Type (2021-2026) & (\$ millions)

Table 57. Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size by
Application (2021-2026) & (\$ millions)

Table 58. Key Market Drivers & Growth Opportunities of Alpha-emitting
Radiopharmaceutical

Table 59. Key Market Challenges & Risks of Alpha-emitting Radiopharmaceutical

Table 60. Key Industry Trends of Alpha-emitting Radiopharmaceutical

Table 61. Global Alpha-emitting Radiopharmaceutical Market Size Forecast by Region
(2027-2032) & (\$ millions)

Table 62. Global Alpha-emitting Radiopharmaceutical Market Size Market Share
Forecast by Region (2027-2032)

Table 63. Global Alpha-emitting Radiopharmaceutical Market Size Forecast by Type
(2027-2032) & (\$ millions)

Table 64. Global Alpha-emitting Radiopharmaceutical Market Size Forecast by
Application (2027-2032) & (\$ millions)

Table 65. Bayer Details, Company Type, Alpha-emitting Radiopharmaceutical Area
Served and Its Competitors

Table 66. Bayer Alpha-emitting Radiopharmaceutical Product Offered

Table 67. Bayer Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin
and Market Share (2021-2026)

Table 68. Bayer Main Business
Table 69. Bayer Latest Developments
Table 70. Novartis Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors
Table 71. Novartis Alpha-emitting Radiopharmaceutical Product Offered
Table 72. Novartis Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 73. Novartis Main Business
Table 74. Novartis Latest Developments
Table 75. Eli Lilly Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors
Table 76. Eli Lilly Alpha-emitting Radiopharmaceutical Product Offered
Table 77. Eli Lilly Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 78. Eli Lilly Main Business
Table 79. Eli Lilly Latest Developments
Table 80. AstraZeneca Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors
Table 81. AstraZeneca Alpha-emitting Radiopharmaceutical Product Offered
Table 82. AstraZeneca Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 83. AstraZeneca Main Business
Table 84. AstraZeneca Latest Developments
Table 85. Fusion Pharmaceuticals Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors
Table 86. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Product Offered
Table 87. Fusion Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 88. Fusion Pharmaceuticals Main Business
Table 89. Fusion Pharmaceuticals Latest Developments
Table 90. Telix Pharmaceuticals Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors
Table 91. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Product Offered
Table 92. Telix Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)
Table 93. Telix Pharmaceuticals Main Business
Table 94. Telix Pharmaceuticals Latest Developments
Table 95. RayzeBio Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors

Table 96. RayzeBio Alpha-emitting Radiopharmaceutical Product Offered

Table 97. RayzeBio Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 98. RayzeBio Main Business

Table 99. RayzeBio Latest Developments

Table 100. Orano Med Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors

Table 101. Orano Med Alpha-emitting Radiopharmaceutical Product Offered

Table 102. Orano Med Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 103. Orano Med Main Business

Table 104. Orano Med Latest Developments

Table 105. Actinium Pharmaceuticals Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors

Table 106. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Product Offered

Table 107. Actinium Pharmaceuticals Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 108. Actinium Pharmaceuticals Main Business

Table 109. Actinium Pharmaceuticals Latest Developments

Table 110. Alpha-9 Theranostics Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors

Table 111. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Product Offered

Table 112. Alpha-9 Theranostics Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 113. Alpha-9 Theranostics Main Business

Table 114. Alpha-9 Theranostics Latest Developments

Table 115. AdvanCell Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors

Table 116. AdvanCell Alpha-emitting Radiopharmaceutical Product Offered

Table 117. AdvanCell Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 118. AdvanCell Main Business

Table 119. AdvanCell Latest Developments

Table 120. ITM Isotope Technologies Munich Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors

Table 121. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical Product Offered

Table 122. ITM Isotope Technologies Munich Alpha-emitting Radiopharmaceutical

Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 123. ITM Isotope Technologies Munich Main Business

Table 124. ITM Isotope Technologies Munich Latest Developments

Table 125. Curium Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors

Table 126. Curium Alpha-emitting Radiopharmaceutical Product Offered

Table 127. Curium Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 128. Curium Main Business

Table 129. Curium Latest Developments

Table 130. China Isotope & Radiation Details, Company Type, Alpha-emitting Radiopharmaceutical Area Served and Its Competitors

Table 131. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Product Offered

Table 132. China Isotope & Radiation Alpha-emitting Radiopharmaceutical Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 133. China Isotope & Radiation Main Business

Table 134. China Isotope & Radiation Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Alpha-emitting Radiopharmaceutical Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Alpha-emitting Radiopharmaceutical Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Alpha-emitting Radiopharmaceutical Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Alpha-emitting Radiopharmaceutical Sales Market Share by Country/Region (2025)

Figure 8. Alpha-emitting Radiopharmaceutical Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Type in 2025

Figure 10. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Indication in 2025

Figure 11. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Supply Form in 2025

Figure 12. Alpha-emitting Radiopharmaceutical in Prostate Cancer

Figure 13. Global Alpha-emitting Radiopharmaceutical Market: Prostate Cancer (2021-2026) & (\$ millions)

Figure 14. Alpha-emitting Radiopharmaceutical in Bone Metastases

Figure 15. Global Alpha-emitting Radiopharmaceutical Market: Bone Metastases (2021-2026) & (\$ millions)

Figure 16. Alpha-emitting Radiopharmaceutical in Neuroendocrine Tumors

Figure 17. Global Alpha-emitting Radiopharmaceutical Market: Neuroendocrine Tumors (2021-2026) & (\$ millions)

Figure 18. Alpha-emitting Radiopharmaceutical in Hematologic Malignancies

Figure 19. Global Alpha-emitting Radiopharmaceutical Market: Hematologic Malignancies (2021-2026) & (\$ millions)

Figure 20. Alpha-emitting Radiopharmaceutical in Other Solid Tumors

Figure 21. Global Alpha-emitting Radiopharmaceutical Market: Other Solid Tumors (2021-2026) & (\$ millions)

Figure 22. Alpha-emitting Radiopharmaceutical in Other

Figure 23. Global Alpha-emitting Radiopharmaceutical Market: Other (2021-2026) & (\$

millions)

Figure 24. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Application in 2025

Figure 25. Global Alpha-emitting Radiopharmaceutical Revenue Market Share by Player in 2025

Figure 26. Global Alpha-emitting Radiopharmaceutical Market Size Market Share by Region (2021-2026)

Figure 27. Americas Alpha-emitting Radiopharmaceutical Market Size 2021-2026 (\$ millions)

Figure 28. APAC Alpha-emitting Radiopharmaceutical Market Size 2021-2026 (\$ millions)

Figure 29. Europe Alpha-emitting Radiopharmaceutical Market Size 2021-2026 (\$ millions)

Figure 30. Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size 2021-2026 (\$ millions)

Figure 31. Americas Alpha-emitting Radiopharmaceutical Value Market Share by Country in 2025

Figure 32. United States Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 33. Canada Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 34. Mexico Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 35. Brazil Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 36. APAC Alpha-emitting Radiopharmaceutical Market Size Market Share by Region in 2025

Figure 37. APAC Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2021-2026)

Figure 38. APAC Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2026)

Figure 39. China Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 40. Japan Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 41. South Korea Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 42. Southeast Asia Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 43. India Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 44. Australia Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 45. Europe Alpha-emitting Radiopharmaceutical Market Size Market Share by Country in 2025

Figure 46. Europe Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2021-2026)

Figure 47. Europe Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2026)

Figure 48. Germany Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 49. France Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 50. UK Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 51. Italy Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 52. Russia Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 53. Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size Market Share by Region (2021-2026)

Figure 54. Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size Market Share by Type (2021-2026)

Figure 55. Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size Market Share by Application (2021-2026)

Figure 56. Egypt Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 57. South Africa Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 58. Israel Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 59. Turkey Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 60. GCC Countries Alpha-emitting Radiopharmaceutical Market Size Growth 2021-2026 (\$ millions)

Figure 61. Americas Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 62. APAC Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$

millions)

Figure 63. Europe Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 64. Middle East & Africa Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 65. United States Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 66. Canada Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 67. Mexico Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 68. Brazil Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 69. China Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 70. Japan Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 71. Korea Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 72. Southeast Asia Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 73. India Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 74. Australia Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 75. Germany Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 76. France Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 77. UK Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 78. Italy Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 79. Russia Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 80. Egypt Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 81. South Africa Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 82. Israel Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 83. Turkey Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

Figure 84. Global Alpha-emitting Radiopharmaceutical Market Size Market Share Forecast by Type (2027-2032)

Figure 85. Global Alpha-emitting Radiopharmaceutical Market Size Market Share Forecast by Application (2027-2032)

Figure 86. GCC Countries Alpha-emitting Radiopharmaceutical Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Alpha-emitting Radiopharmaceutical Market Growth (Status and Outlook)
2026-2032

Product link: <https://marketpublishers.com/r/G66C959EDF74EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer
Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click
button on product page <https://marketpublishers.com/r/G66C959EDF74EN.html>